[go: up one dir, main page]

AR048822A1 - Emulsiones de aceite en agua microfluidizadas y composiciones de las vacunas - Google Patents

Emulsiones de aceite en agua microfluidizadas y composiciones de las vacunas

Info

Publication number
AR048822A1
AR048822A1 ARP050101316A AR048822A1 AR 048822 A1 AR048822 A1 AR 048822A1 AR P050101316 A ARP050101316 A AR P050101316A AR 048822 A1 AR048822 A1 AR 048822A1
Authority
AR
Argentina
Prior art keywords
microfluidized
oil emulsions
vaccine compositions
water oil
emulsions
Prior art date
Application number
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048822(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR048822A1 publication Critical patent/AR048822A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Emulsiones submicrométricas de aceite en agua de utilidad como adyuvante de vacuna para potenciar la capacidad inmunogena de antígenos. Composiciones de las vacunas que contienen un antígeno combinado con tales emulsiones de forma intrínseca o extrínseca. Procedimientos para preparar las emulsiones y vacunas. Reivindicacion 1: Una vacuna que comprende un glucosido de saponina, un esterol y un antígeno, en la que dicho glucosido de saponina y dicho esterol se asocian entre sí para formar complejos en forma de micelas helicoidales y en la que dicho antígeno está mezclado, pero no integrado, en dichas micelas helicoidales.
ARP050101316 2004-04-05 2005-04-04 Emulsiones de aceite en agua microfluidizadas y composiciones de las vacunas AR048822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55967704P 2004-04-05 2004-04-05

Publications (1)

Publication Number Publication Date
AR048822A1 true AR048822A1 (es) 2006-05-31

Family

ID=34961993

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101316 AR048822A1 (es) 2004-04-05 2005-04-04 Emulsiones de aceite en agua microfluidizadas y composiciones de las vacunas

Country Status (22)

Country Link
US (1) US7122191B2 (es)
EP (2) EP1742659B1 (es)
JP (2) JP5393978B2 (es)
KR (5) KR20110132416A (es)
CN (1) CN1997390B (es)
AR (1) AR048822A1 (es)
AU (1) AU2005230708B2 (es)
BR (1) BRPI0509606B1 (es)
CA (1) CA2561914C (es)
DK (1) DK1742659T3 (es)
ES (1) ES2409782T3 (es)
NO (1) NO341034B1 (es)
NZ (1) NZ550152A (es)
PL (1) PL1742659T3 (es)
PT (1) PT1742659E (es)
RU (1) RU2347586C2 (es)
SI (1) SI1742659T1 (es)
TW (1) TWI301067B (es)
UA (1) UA89631C2 (es)
UY (1) UY28840A1 (es)
WO (1) WO2005097181A1 (es)
ZA (1) ZA200608200B (es)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
AU2002214861B2 (en) 2000-11-07 2006-09-28 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AR044732A1 (es) * 2002-11-08 2005-10-05 H P B S A Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
CN1997390B (zh) * 2004-04-05 2012-10-10 辉瑞产品有限公司 微流化水包油乳状液和疫苗组合物
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US20070042001A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE06808434T1 (de) 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
EP1792619A1 (en) * 2005-11-28 2007-06-06 Laboratorios Maymo, S.A. Beta-sitosterol for treating porcine respiratory disease complex
NZ570106A (en) 2006-01-27 2012-04-27 Novartis Vaccines & Diagnostic Influenza vaccines containing hemagglutinin and matrix proteins
EP1988918A4 (en) * 2006-02-22 2010-04-28 Novavax Inc ADJUVANZ AND VACCINE COMPOSITIONS
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CN102137675A (zh) 2008-04-17 2011-07-27 Pds生物科技公司 通过阳离子脂质的对映体刺激免疫应答
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
CN104758929B (zh) * 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物
AU2012258478B2 (en) * 2008-06-27 2013-10-03 Zoetis Services Llc Novel adjuvant compositions
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
CN105727281A (zh) 2009-02-10 2016-07-06 诺华股份有限公司 具有减少量的角鲨烯的流感疫苗
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
JP2012519482A (ja) 2009-03-06 2012-08-30 ノバルティス アーゲー クラミジア抗原
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
ES2394797T3 (es) 2009-05-21 2013-02-05 Novartis Ag Genética inversa usando promotores no endógenos de pol l
EA201171491A1 (ru) 2009-05-29 2012-07-30 Новартис Аг Анализы гемагглютининов вируса гриппа
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
EP3178490B1 (en) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US8871214B2 (en) 2009-07-16 2014-10-28 Novartis Ag Detoxified Escherichia coli immunogens
KR20120039047A (ko) 2009-07-31 2012-04-24 노파르티스 아게 역유전학 시스템
CA2770570A1 (en) * 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
EA023811B1 (ru) 2009-10-20 2016-07-29 Новартис Аг Способ получения вируса с использованием конструкции, кодирующей вирусную рнк
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US12370251B2 (en) 2009-11-05 2025-07-29 Mercia Pharma, Inc. Adjuvanted nanoparticulate influenza vaccine
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
DK2356983T3 (da) 2009-12-03 2013-03-11 Novartis Ag Cirkulation af bestanddele under homogenisering af emulsioner
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PL2343052T3 (pl) 2009-12-03 2013-11-29 Novartis Ag Hydrofilowa filtracja podczas produkcji adiuwantów do szczepionek
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
CN101926994B (zh) * 2010-08-19 2012-10-10 中国医学科学院医学生物学研究所 一种鳖甲免疫佐剂及含有该佐剂的流感疫苗
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
DK2667892T3 (da) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV-vaccineringsprogram
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
EP2791680B1 (en) 2011-12-12 2015-12-09 Novartis AG Assay for influenza virus hemagglutinins
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
EP2820126B1 (en) 2012-03-02 2017-05-17 Seqirus UK Limited Influenza virus reassortment
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
EP3632464A1 (en) 2012-06-15 2020-04-08 PDS Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
PL2890394T3 (pl) 2012-08-31 2019-12-31 Glaxosmithkline Biologicals Sa Stabilizowane białka do immunizacji przeciw staphylococcus aureus
JP2015528456A (ja) 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
WO2014056885A1 (en) 2012-10-09 2014-04-17 Universiteit Gent Cooperia vaccine
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
SG11201504258RA (en) 2012-11-30 2015-07-30 Glaxosmithkline Biolog Sa Pseudomonas antigens and antigen combinations
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
CA2905612A1 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
KR20160014657A (ko) 2013-06-06 2016-02-11 노파르티스 아게 인플루엔자 바이러스 재배열
KR20190009840A (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
US20160256540A1 (en) 2013-10-17 2016-09-08 Zoetis Services Llc Methods And Compositions For Treatment Of S. Equi Infection
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2014354967B2 (en) * 2013-11-26 2019-04-11 Zoetis Services Llc Compositions for induction of immune response
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
KR102297357B1 (ko) 2014-03-26 2021-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
SI3244920T1 (sl) 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
BR112017028011A2 (en) 2015-06-26 2018-08-28 Seqirus UK Limited antigenically matched influenza vaccines
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation LIPIDES AS SYNTHETIC VECTORS FOR IMPROVING ANTIGEN PROCESSING AND PRESENTATION EX-VIVO IN DENDRITIC CELL THERAPY
RU2018137034A (ru) * 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
CA3022006A1 (en) * 2016-05-11 2017-11-16 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
EP4479088A1 (en) 2022-02-14 2024-12-25 University of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5690942A (en) 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ATE286511T1 (de) * 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
HK1044484B (en) * 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
DE10106446A1 (de) * 2001-02-09 2002-10-10 Haarmann & Reimer Gmbh Verfahren zur Herstellung blauer Mikrokapseln
WO2004017990A1 (en) * 2002-08-26 2004-03-04 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
PL378001A1 (pl) * 2003-01-29 2006-02-20 Pfizer Products Inc. Szczepionki przeciw Bordetella bronchiseptica dla psów
BRPI0408635B1 (pt) * 2003-04-04 2019-07-16 Zoetis Services Llc Método de preparação de uma emulsão de óleo em água microfluidizada na faixa dos submicrômetros com um tamanho médio de gotícula de óleo inferior a 0,5 ?m, emulsão de óleo em água microfluidizada, método de preparação de uma composição de vacina microfluidizada e composições de vacina microfluidizadas
CN1997390B (zh) * 2004-04-05 2012-10-10 辉瑞产品有限公司 微流化水包油乳状液和疫苗组合物

Also Published As

Publication number Publication date
KR101143060B1 (ko) 2012-05-08
KR20070008625A (ko) 2007-01-17
JP2011168605A (ja) 2011-09-01
ES2409782T3 (es) 2013-06-27
EP2269644A2 (en) 2011-01-05
NO20065039L (no) 2006-11-02
US7122191B2 (en) 2006-10-17
TW200600108A (en) 2006-01-01
JP2007531790A (ja) 2007-11-08
ZA200608200B (en) 2008-09-25
UY28840A1 (es) 2005-11-30
EP1742659B1 (en) 2013-03-13
AU2005230708B2 (en) 2009-01-15
BRPI0509606A (pt) 2007-09-18
CN1997390B (zh) 2012-10-10
DK1742659T3 (da) 2013-06-03
CN1997390A (zh) 2007-07-11
KR20090051129A (ko) 2009-05-20
WO2005097181A1 (en) 2005-10-20
NZ550152A (en) 2009-04-30
TWI301067B (en) 2008-09-21
KR20080073376A (ko) 2008-08-08
RU2006135121A (ru) 2008-04-10
PL1742659T3 (pl) 2013-08-30
KR20090007497A (ko) 2009-01-16
EP2269644A3 (en) 2012-10-17
AU2005230708A1 (en) 2005-10-20
BRPI0509606B1 (pt) 2019-01-15
JP5393978B2 (ja) 2014-01-22
KR20110132416A (ko) 2011-12-07
RU2347586C2 (ru) 2009-02-27
EP1742659A1 (en) 2007-01-17
PT1742659E (pt) 2013-06-03
NO341034B1 (no) 2017-08-07
HK1108830A1 (en) 2008-05-23
UA89631C2 (en) 2010-02-25
US20050220814A1 (en) 2005-10-06
CA2561914C (en) 2013-09-10
CA2561914A1 (en) 2005-10-20
SI1742659T1 (sl) 2013-07-31

Similar Documents

Publication Publication Date Title
AR048822A1 (es) Emulsiones de aceite en agua microfluidizadas y composiciones de las vacunas
AR058543A1 (es) Nueva composicion de vacuna potenciada con un adyuvante liposomal
Kersten et al. Liposomes and ISCOMS
UY28256A1 (es) Emulsiones de aceite en agua microfludizadas y composiciones de vacunas
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
TW200700079A (en) Composition
CL2015002157A1 (es) Una composición inmunogenica que comprende: un sacárido capsular pneumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antígeno de proteína de unión a factor h (fhbp) menincocócico, pero sin incluir vesículas de membrana meningocócica; metodo de preparación de la composición
AR052498A1 (es) Vacuna
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
HRP20120433T1 (en) Meningococcal vaccine formulations
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
WO2010016912A3 (en) Immunotherapeutic compositions for the treatment of alzheimer's disease
AR108718A2 (es) Composición
WO2007002886A3 (en) Compositions and methods for less immunogenic pr0tein-lip1d complexes
AR023536A1 (es) Vacunas
CU23377A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
TH72570B (th) อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน
WO2005072679A3 (es) Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
MY139811A (en) Subcutaneously - administered ganglioside-based vaccine compositions
TH79421A (th) อิมัลชันของน้ำมันในน้ำชนิดผ่านการไมโครฟลูอิดไดซ์ และองค์ประกอบของวัคซีน
TH94291A (th) สารผสมวัคซีนที่ได้เสริมฤทธิ์โดยที่สารเสริม คือ สูตรผสมไลโปโซมที่ประกอบรวมด้วยซาโปนิน และไลโปพอลิแซ็กคาไรด์
HK1141793A (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
BR0304989A (pt) Composições fitoterápicas à base de plantas, processo de obtenção das ditas composições e uso de plantas para preparação das composições fitoterápicas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal